by Brian Shilhavy, Health Impact News:
Tens of thousands of mothers are suing the makers of Tylenol for using the popular over-the-counter pain reliever during pregnancy, which resulted in them giving birth to babies diagnosed with autism.
Tens of thousands of mothers are suing the makers of Tylenol in a class-action lawsuit that claims its use during pregnancy led babies to be born with autism.
A study from the NIH found that pregnancy exposure to acetaminophen, the main ingredient in Tylenol, may increase a child’s risk for autism and ADHD.
Karleen DeGroodt is among the mothers in the lawsuit and discussed her use of Tylenol during pregnancy and her son’s autism during an appearance on NewsNation’s “Prime.” (Full article.)
Last October, a federal judicial panel consolidated dozens of these lawsuits alleging that acetaminophen, the active ingredient in Tylenol and generic versions of the drug, can cause autism spectrum disorder and attention deficit hyperactivity disorder.
TRUTH LIVES on at https://sgtreport.tv/
TorHoerman Law is one of the law firms representing these mothers, and they have produced the following video explaining the lawsuit.
The main defendant in the lawsuit is Kenvue, which is the former Johnson & Johnson’s consumer health unit that is now a “spin-off” of J&J. (Source)
Co-defendants in the lawsuit are CVS Health, Rite Aid Corp, Safeway Inc, Target Corp and Walgreens Boots Alliance, which are being charged with failing to warn consumers about the risks of Tylenol.
Kenvue has suffered some setbacks in recent weeks in trying to get some of the lawsuits dismissed, with one of the reasons given to dismiss the lawsuits being that the FDA had approved the product and its labels.
Kenvue Inc cannot immediately appeal a federal judge’s order allowing lawsuits claiming that its popular over-the-counter painkiller Tylenol can cause autism in children of mothers who take it during pregnancy, the judge has ruled.
U.S. District Judge Denise Cote in Manhattan on Thursday ruled that Kenvue, formerly Johnson & Johnson’s consumer health unit, had not shown any basis for allowing the unusual step of an appeal to the 2nd U.S. Circuit Court of Appeals before final judgment in the case.
In April, Cote denied Kenvue’s motion to dismiss one of the lawsuits on the grounds that the U.S. Food and Drug Administration’s approval of Tylenol’s label preempted any state law claims. Had she ruled in the company’s favor, it would have ended the entire litigation. (Source.)
The amount of studies published in the medical journals linking Tylenol taken during pregnancy to babies born with autism is overwhelming.
Here are just a couple of the more recent studies published this year (2023).
Acetaminophen causes neurodevelopmental injury in susceptible babies and children: no valid rationale for controversy
Clinical and Experimental Pediatrics – June 14, 2023
Abstract
Despite worldwide acceptance of acetaminophen as a necessary medicine in the field of pediatrics, evidence that early life exposure to acetaminophen causes neurodevelopmental injury in susceptible babies and children has mounted for more than a decade.
Evidence is diverse, including extensive work with laboratory animals, otherwise unexplained associations, factors associated with the metabolism of acetaminophen, and some limited studies in humans. Although evidence has reached an overwhelming level and has been reviewed in detail recently, some controversy remains. In this narrative review, some of those controversies are evaluated.
Read More @ HealthImpactNews.com
